181 related articles for article (PubMed ID: 24740245)
1. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.
Buil-Bruna N; López-Picazo JM; Moreno-Jiménez M; Martín-Algarra S; Ribba B; Trocóniz IF
AAPS J; 2014 May; 16(3):609-19. PubMed ID: 24740245
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
[TBL] [Abstract][Full Text] [Related]
3. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
Jørgensen LG; Osterlind K; Hansen HH; Cooper EH
Br J Cancer; 1994 Oct; 70(4):759-61. PubMed ID: 7917935
[TBL] [Abstract][Full Text] [Related]
4. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
6. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
Quoix E; Purohit A; Faller-Beau M; Moreau L; Oster JP; Pauli G
Lung Cancer; 2000 Nov; 30(2):127-34. PubMed ID: 11086206
[TBL] [Abstract][Full Text] [Related]
7. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer.
Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R
Respiration; 1997; 64(1):102-7. PubMed ID: 9044484
[TBL] [Abstract][Full Text] [Related]
8. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
[TBL] [Abstract][Full Text] [Related]
9. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
10. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
11. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
12. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Ray P; Quantin X; Grenìer J; Pujol JL
Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
[TBL] [Abstract][Full Text] [Related]
14. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of serum NSE (neuron specific enolase) levels in cases of small cell lung cancer].
Moriya H; Hisa S; Satoh T; Suzuki S; Kimura K; Higuchi Y; Hoshi K
Rinsho Hoshasen; 1988 Jan; 33(1):31-4. PubMed ID: 2835529
[No Abstract] [Full Text] [Related]
17. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
18. Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer.
Abbasciano V; Sartori S; Trevisani L; Nielsen I; Ferrazzi E; Bononi A; Toso S; Crepaldi G; Bianchi MP; Gilli G; Zavagli G
Cancer Detect Prev; 1999; 23(4):309-15. PubMed ID: 10403902
[TBL] [Abstract][Full Text] [Related]
19. Neuron-specific enolase (NSE) as a tumour marker and comparative evaluation with carcinoembryonic antigen (CEA) in small-cell lung cancer.
Adewole IF; Newlands ES
Med Oncol Tumor Pharmacother; 1987; 4(1):11-5. PubMed ID: 3037205
[TBL] [Abstract][Full Text] [Related]
20. Early Prediction of Disease Progression in Small Cell Lung Cancer: Toward Model-Based Personalized Medicine in Oncology.
Buil-Bruna N; Sahota T; López-Picazo JM; Moreno-Jiménez M; Martín-Algarra S; Ribba B; Trocóniz IF
Cancer Res; 2015 Jun; 75(12):2416-25. PubMed ID: 25939602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
